Drug intelligence / Profile preview

Aggregon Oncoquest

Development stage
Unknown
Lead developer
R2T BIOPHARMA
Modality
Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration
Subcutaneous
01

Overview

**Aggregon Oncoquest** is a personalized autologous therapeutic cancer vaccine developed using XEME Biopharma's Aggregon multilamellar liposome technology. Each patient-specific product incorporates tumor-cell lysate and/or tumor-specific neoantigens derived from the patient's own cancer together with recombinant human interleukin-2, with the aim of promoting antigen presentation and expanding tumor-reactive T-cell responses. Clinical variants include Oncoquest-CLL for treatment-naive chronic lymphocytic leukemia and Oncoquest-L for previously untreated, asymptomatic, non-bulky stage III or IV follicular lymphoma; an ovarian-cancer program has also been proposed.

Other names
Oncoquest
02

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on Aggregon Oncoquest.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aggregon Oncoquest.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call